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Down syndrome (DS) is themost common cause of mental retardation. Many neural phenotypes are shared between DS individuals and
DS mouse models; however, the common underlying molecular pathogenetic mechanisms remain unclear. Using a transchromosomic
model of DS, we show that a 30%–60% reduced expression of Nrsf/Rest (a key regulator of pluripotency and neuronal differentiation) is
an alteration that persists in trisomy 21 from undifferentiated embryonic stem (ES) cells to adult brain and is reproducible across several
DS models. Using partially trisomic ES cells, we map this effect to a three-gene segment of HSA21, containing DYRK1A. We indepen-
dently identify the same locus as themost signiﬁcant eQTL controlling RESTexpression in the human genome.We show that speciﬁcally
silencing the third copy of DYRK1A rescues Rest levels, and we demonstrate altered Rest expression in response to inhibition of DYRK1A
expression or kinase activity, and in a transgenicDyrk1Amouse. We reveal that undifferentiated trisomy 21 ES cells showDYRK1A-dose-
sensitive reductions in levels of some pluripotency regulators, causing premature expression of transcription factors driving early endo-
dermal andmesodermal differentiation, partially overlapping recently reported downstream effects of Restþ/. They produce embryoid
bodies with elevated levels of the primitive endodermprogenitormarkerGata4 and a strongly reduced neuroectodermal progenitor com-
partment. Our results suggest that DYRK1A-mediated deregulation of REST is a very early pathological consequence of trisomy 21 with
potential to disturb the development of all embryonic lineages, warranting closer research into its contribution to DS pathology and new
rationales for therapeutic approaches.Introduction
Down syndrome (DS [MIM 190685]) is a complex condi-
tion characterized by many phenotypic features, including
mental retardation, smaller brain size, reduced numbers of
neurons, reduced dendritic spine density and plasticity,
and early-Alzheimer’s-disease-like neurodegeneration.1,2
Mouse models for DS also display behavioral and cognitive
defects, synaptic plasticity defects and long-term potentia-
tion (LTP) deﬁcit in the hippocampus, and reduced hippo-
campal and cerebellar neuron numbers.3–8 However,
despite these similarities, causative mechanisms common
to human and mouse DS systems remain to be elucidated.
Cultured fetal DS brain cell-derived neurospheres were
found to have decreased transcript levels of neuron-restric-
tive silencer factor (NRSF or REST [MIM 600571]) and
downstream targets such as SCG109[MIM 600621]. REST
modulates expression of genes encoding fundamental
neuronal functions including ion channels, synaptic pro-
teins, and neurotransmitter receptors.10–15 It is essential
both for the repression of these genes in non-neuronaltissues10 and for the orchestrated activation of transcrip-
tion of these genes during neuronal differentiation, acting
as a silencer or as a transcription activator.12–14,16–18 Coor-
dinated activation of transcription of REST targets is both
necessary and sufﬁcient for the transition from pluripotent
embryonic stem (ES) cells to neural progenitor cells
(NPCs)14 and onward to mature neurons,13,14 and the
REST pathway has been implicated in an inherited form
of mental retardation.19 Using a transchromosomic mouse
model of DS, we show here that a reduced expression of
Rest is an alteration that persists from undifferentiated ES
cells to the adult brain and is reproducible across several
DS models. We map the region capable of affecting Rest
levels in both mouse and human cells to the DYRK1A
[MIM 600855] locus and demonstrate the sensitivity of
Rest levels to the dose and kinase activity of DYRK1A. Re-
cently, Rest þ/ cells were found to have reduced levels
of key pluripotency regulators (Oct4 [MIM 164177], Nanog
[MIM 607937] and Sox2 [MIM 184429]), shedding new
light on the function of Rest in the regulation of ES cell
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trisomy 21 ES cells share certain aspects of the aberrant
control of pluripotency and early differentiation reported
in Rest þ/ cells,20 suggesting that DYRK1A-mediated
deregulation of REST could be an important potential
contributor to a variety of DS phenotypes.
Material and Methods
Material
All general reagents and tissue-culture media were from Sigma
(Dorset, UK) unless otherwise stated, and all primers were supplied
by Invitrogen (Paisley, UK). Transchromosomic ES cells 47-1, 40-2,
and 46-1 were derived from D3 ES cells by the introduction of all
or parts of HSA21 via microcell-mediated chromosome transfer.21
Mapping data for 40-2 and 46-1 have been previously published,21
and they were veriﬁed and reﬁned to the single-gene resolution in
the current study (data available upon request). Antibodies were as
follows: anti-REST from Upstate, anti-GAPDH from Invitrogen
(ZYMED laboratories), and anti-PTEN from Abcam. Anti-b-actin,
anti-calnexin, and anti-b tubulin isotype III antibodies were
from Sigma. Sequences of primers and probes used for quantitative
RT-PCR and linkage analysis are available in Table S3, available
online. EGCG (epigallocatechin gallate) was from Sigma. The
Dual-Luciferase Reporter Assay System was from Promega.
Mice
Tc1 mice backcrossed to C57BL/6J (2–3 generations) and Ts1Cje
mice backcrossed to C57BL/6J (> 10 generations) weremaintained
at the National Institute for Medical Research in accordance with
UK Home Ofﬁce regulations.8 The TgDyrk1A mice were main-
tained on C57BL6/SJL background in the facility of the Genes
and Disease Program, Center for Genomic Regulation. Whole
brain hemispheres from 6- to 11-month-old adult mice were
used. In all comparisons, sex-matched littermates were used.
ES Cell Culture and Differentiation
Pluripotent D3 and 47-1 ES cells were seeded onto embryonic-ﬁ-
broblast feeder layers and were maintained in DMEM with 15%
fetal-calf serum (Hyclone), 2 mM glutamine, 1 3 nonessential
amino acids (Invitrogen), 50 U/ml penicillin, 50 mg/ml streptomy-
cin, 1:150,000 b-mercaptoethanol, and 103 U/ml LIF-ESGRO
(Chemicon). For the ﬁrst passage, transchromosomic cells were
cultured in ES medium with 500 mg/ml G418 for ensuring reten-
tion of HSA21. Cells were cultured without G418 for a second
passage, for minimization of differences in culture conditions be-
tween wild-type (WT) and transchromosomic cells, and without
G418 or feeders for the ﬁnal passage before extraction, for minimi-
zation of background from feeder cells. Transchromosomic cells
were veriﬁed by FISH as retaining HSA21 in > 90% of cells, with
the use of human Cot1 probe as described previously.21 For differ-
entiation into NPCs, D3 and 47-1 cells were treated as described.22
In brief, cells were cultured in the absence of LIF to form embryoid
bodies, which were then treated with 5 mMRA for four days before
dissociation22 and replating onto poly-D-lysine- and laminin-
coated dishes in Neurobasal N2 medium (Invitrogen).
Immunoﬂuorescence was carried out as described.14 Images
were captured with the use of a Q550 Imaging Workstation with
DM5000 microscope and Qwin v3.2 software (Leica Microsystems
[UK], Bucks). For cell counts and neurite characterization, 10–15
different images of each of the D3 and 47-1 cell lines from inde-The Americanpendent neural-differentiation experiments were collected by
automated unbiased random sampling (total of 30 images per
cell line). Mature neurons, identiﬁed by immunoﬂuorescent stain-
ing, were counted blindly by two researchers and expressed rela-
tive to DAPI-staining nuclei. Similar numbers of D3 and 47-1 cells
were counted (ranging from 400–3000 cells per experiment).
Microarray Analysis
RNA was extracted from four cultures of each cell line in undiffer-
entiated state with the use of RNEasy mini spin columns with
on-column Dnase-1 digestion (QIAGEN, Crawley, UK) and labeled
according to the standard Affymetrix protocol before hybridiza-
tion to MG-U74Av2 microarrays (Affymetrix UK, High Wycombe,
UK). Images were scaled to a target intensity of 500, and all sam-
ples were veriﬁed as having Gapdh [MIM 138400] and b-actin
[MIM 102630] 30/50 ratios less than 3 and at least 40% of probe
sets called present (range 40.3–51.1). All array data have been
deposited in the MIAMExpress database, under the experiment
number ‘E-MEXP-654’.
Differentially expressed genes were identiﬁed with two different
search strategies. In the ﬁrst, absolute and comparative data were
exported from Affymetrix MicroArray Suite (MAS) software into
a microarray-analysis program based on Filemaker Pro 5 (File-
maker), developed by G.D. A search was carried out for probe sets
called ‘‘increased’’ or ‘‘decreased’’ by MAS (change p value < 0.05)
in all comparisons between 47-1 and D3 cells, with the highest sig-
nal being called ‘‘present’’ in each case. In the secondmethod, abso-
lutedatawere imported intoGenespringv6.1 (SiliconGenetics,CA,
USA), normalized to the 50th percentile of each array, and normal-
ized to themedian for eachprobe set. Thedatawere thenﬁltered for
removal of all probe sets that were called present in fewer than four
samples and those that changed fewer than two times between the
twocell lines. ANOVAwas applied to the remainingprobe sets,with
the Benjamini-Hochberg multiple-testing correction.
Quantitative RT-PCR
RNA from mouse brains was extracted with RNABee (Tel-Test,
Texas, USA), according to the manufacturer’s protocol, followed
by DNase-1 digestion (Roche) and cDNA synthesis with Super-
script II reverse transcriptase (Invitrogen). RNA from D3 and
47-1 cells was extracted with the use of the RNeasy Plus Mini Kit
(QIAGEN). Quantitative RT-PCR was carried out via an Applied
Biosystems 7700 Sequence Detector v1.7 and SYBR green or Taq-
man PCR mix, according to the manufacturer’s protocol (Applied
Biosystems, Warrington, UK). All transcripts were measured in
duplicate against standard curves relative to Gapdh.
RNAi Silencing
Knockdown ofDYRK1A, Ttc3 [MIM 602259],Dscr3 [MIM 605298],
Setd4, and Cbr1[MIM 114830] was achieved by transfection of
RNAi oligonucleotides with Lipofectamine 2000 (Invitrogen), ac-
cording to the manufacturer’s speciﬁc protocol for D3 cells with
minor modiﬁcations. In brief, ES cells were trypsinized, pelleted
by centrifugation, and resuspended in ES cell medium. Then, 5 3
105 cells were seeded into previously gelatinized 12-well plates,
and a transfectionmixture containing 4 mg of Lipofectamine-2000
and 100 pmol of the speciﬁc sequence (or scrambled sequence) of
RNAi reagents in Opti-MEM I Reduced Serum Medium was added
to each sample. Samples were incubated for 24 hr before RNA ex-
traction was performed. RNAi oligonucleotide sequences are avail-
able in Table S4.Journal of Human Genetics 83, 388–400, September 12, 2008 389
Figure 1. Transcript Profiling and Analysis of Rest Levels in Down Syndrome Model Systems
(A) Unsupervised clustering of transchromosomic (þHSA21) 47-1 and normal control D3 mouse ES cell lines. RNA samples from four
cultures of each cell line were analyzed independently on Affymetrix MG-U74Av2 arrays, and hierarchical clustering based on Spearman
correlation was performed, after elimination of all probe sets called absent across all chips.
(B) qRT-PCR measurement of the level of Rest transcript in undifferentiated ES cells (n ¼ 9 independent cultures).
(C) qRT-PCR analysis of alternative forms of the Rest transcript (Rest-1 and Rest-4) in undifferentiated ES cells (n ¼ 4).
(D) Western blot of Rest protein expression in undifferentiated ES cells. Bars show densitometric intensity of the Rest band, normalized
against each of the three normalizing protein bands (shown below) and averaged across values obtained from three independent cell
cultures for each normalization.
(E) qRT-PCR analysis of Rest in partially trisomic transchromosomic ES lines 40-2 and 46-1, compared with D3 and 47-1 (n ¼ 4).
(F) Map showing regions of HSA21 that are trisomic (black bar indicates HSA21 fragments [mapping data based on refs. 8,21, Table S5, and
unpublished data]; red bar indicates equivalent mouse chromosome 16 segment5) in trisomy 21 models. The box delineates the minimal
trisomic region correlating with Rest suppression.
390 The American Journal of Human Genetics 83, 388–400, September 12, 2008
Luciferase Assay
Mouse Rest transcript NM_011263 promoter sequence (1013 bp)
was inserted into the PGL-3 basic vector, upstream of the ﬁreﬂy
Luciferase reporter gene. Rest-PGL-3 was cotransected with the
pRL-CMV expression vector into D3 cells with Lipofectamine
2000 (Invitrogen), according to the manufacturer’s speciﬁc proto-
col for D3 cells with minor modiﬁcations. Luciferase activity was
measured with the Dual-Luciferase Reporter assay system (Prom-
ega). Renilla luciferase activity was used for standardization of
transfection efﬁciency.
Protein Analysis
For Western blotting, D3 and 47-1 ES cells were solubilized in 30
mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM phenylmethylsulfonyl
ﬂuoride (PMSF), 1 mM NaF, 1 mg/ml leupeptin, and 5 KU/ml apro-
tinin containing 1% Triton X-100. The lysate was clariﬁed by
centrifugation at 435,0003 g max for 30min at 4C. Immunoblot
analyses were performed as described previously.23 Western
blotting of brain homogenates was performed as described
previously.24
Human-Genome Linkage Analysis
EBV-transformed cell lines of 135 individuals from tenCEPH (Cen-
tre d’Etude du Polymorphisme Humain) pedigrees were obtained
from the Coriell cell repositories. Cell culture and RNA extractions
were performed as described previously.25 Gene-expression levels
of REST and four normalization genes (AGPAT1 [MIM 603099],
B2M [MIM 109700], EEF1A1 [MIM 130590] and UBE2D2 [MIM
602962]) were measured by Taqman qRT-PCR with six replicates
per gene per sample, and expression values were median normal-
ized with q-base software, as described previously.26 Normalized
gene-expression values were used for performing quantitative
multipoint genome-wide linkage analysis with theMerlin package
with the –VC option and default parameters.
Results
Decrease in Rest Level Is an Early and Persistent
Phenotype of Trisomy 21
We sought to examine transcripts altered by trisomy 21 in
pluripotent, undifferentiated mouse ES cells. For this pur-
pose, we compared the transchromosomic mouse ES cell
line 47-1, which was engineered to contain a whole
HSA21 on an otherwise euploid mouse genome,21 with pa-
rental D3 cells using Affymetrix MG-U74Av2 mouse arrays
(n ¼ 4). Unsupervised hierarchical clustering successfully
segregated 47-1 from D3, indicating a global perturbation
of transcription by trisomy 21 (Figure 1A). Rest was found
among the eight most signiﬁcantly decreased mouse tran-
scripts (Figure S1 and Tables S1 and S2). Given that Rest
had previously been found reduced only in DS fetal brain
cells,9 its apparent reduction in pluripotent ES cells would
provide a new insight; we decided to investigate this fur-
ther. Rest suppression in 47-1 cells was veriﬁed by quantita-
tive RT-PCR (Figure 1B). Both alternatively spliced forms ofthe transcript (Rest 1 and Rest 4) were signiﬁcantly de-
creased (Figure 1C; see Table S3 for all primer sequences),
suggesting that suppression occurs at the level of transcrip-
tion rather than alternative splicing. Suppression of Rest
protein was veriﬁed by Western blotting of whole cell ly-
sates, in which a single 200 kD band was seen (Figure 1).
Rest protein level was highly signiﬁcantly reduced, by >
40%, irrespective of the protein used for normalization
(Gapdh, Calnexin, Pten, or all three; Figure 1D). In order
to prove that Rest suppression is not simply a clone- or sys-
tem-speciﬁc artifact, we measured Rest transcript levels in
an independently derived transchromosomic ES cell line
carrying a smaller portion of HSA21 (40-2)21 and in adult
brains from two independent mouse models of DS: (1)
transchromosomic Tc1 mice, which model a range of
features of DS, including changes in behavior, synaptic
plasticity, cerebellar neuronal number, congenital heart
defects, and skeletal malformations;8 and (2) Ts1Cje
mice, which are trisomic for a segment of mouse chromo-
some 16 carryingmouse orthologs of 85 HSA21 genes5 and
display DS neurological phenotypes similar to those of Tc1
mice.5–7 All three systems showed a 34%–41% reduction of
Rest transcript levels compared to WT (Figures 1E–1G).
Other tissues of the DS mouse models also showed a de-
crease in Rest and altered dose of some of the genes con-
taining NSRE elements27 that Rest binds to (examples
shown in Figure S2).Therefore, Rest suppression persists
from ES cells to the adult brain, it is reproducible regardless
of differences in genetic background and the species of
origin of the extra chromosome, and, importantly, it is
a phenotype shared between several DS mouse models
(Figure 1F, Figure S2) and human DS.9
Rest-Level Control Maps to DYRK1A Locus in Mouse
ES Cells and Human Lymphoblastoid Lines
Combining results from the different model systems
yielded a minimal trisomic region sufﬁcient to cause Rest
suppression, mapped to a ~2 Mb HSA21 interval. In order
to dissect this region further, we used another ES cell line
(46-1), from the same panel as 40-2, which is not trisomic
for three genes in the candidate region. Because this cell
line showed no signiﬁcant reduction in Rest levels
(Figure 1E), the minimal candidate region for Rest reduc-
tion could be mapped to only three genes: TTC3, DSCR3,
and DYRK1A (Figure 1F).
As an alternative, independent approach to identifying
loci that regulate REST-gene expression, we undertook a
human genome-wide eQTL analysis.25,28,29 We measured
variation of REST transcript levels in human lymphoblas-
toid cell lines of 135 individuals from ten three-generation
CEPH families. Interindividual differences in REST expres-
sion were observed (variance ratio¼ 4.7), with a signiﬁcant
proportion of this variability having a genetic component(G) qRT-PCR analysis of Rest in adult brains of Tc1 mice and their WT littermates (n ¼ 5) and in adult brains of Ts1Cje mice and their WT
littermates (n¼ 6). In all graphs, means and standard errors are shown, and statistical significance by Student’s t test is indicated by one
(p < 0.05), two (p < 0.01), or three (p < 0.001) asterisks.
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Figure 2. Rest Levels Are Controlled by the DYRK1A Genomic Locus in Human Cells and Are Sensitive to DYRK1A Levels in Normal
Mouse Cells
(A) Table showing most significant human genome-wide eQTLs for REST expression levels. The four columns show the chromosome where
the peak is located, the genetic map position of the SNP marker with the highest LOD score, its physical position according to the hg17
assembly, and the corresponding LOD score, respectively.
(B) Results of multipoint REST eQTL analysis of HSA21. Dotted lines show the interval of most significant linkage genome-wide and the
corresponding annotated gene content derived from the UCSC genome browser. The highlighted box indicates overlap with the common
trisomic region identified by segmental models in Figure 1F.
(C) Individual and combination gene-by-gene dissection of the candidate overlap region with the use of RNAi silencing in normal mouse
E14 ES cells. The RNAi targets are indicated along the horizontal axis, and the vertical bars show the qRT-PCR levels for Rest (n ¼ 3
independent transfection experiments). The specificity and efficiency of silencing is shown in Figure S3. Data are shown normalized
to control samples transfected with a nontargeting ‘‘scrambled’’ RNAi sequence. Means and standard errors are shown, and statistical
significance by Student’s t test is indicated by one (p < 0.05) or two (p < 0.01) asterisks.(heritability¼ 0.64; p¼ 3E-6). We performed genome-wide
quantitative linkage analysis using a set of 2688 autosomal
SNPs30 distributed throughout the human genome. Inter-
estingly, the highest LOD score (LOD ¼ 3.81; p ¼ 1.4E-5;
Figure 2A) mapped to a 3 Mb genomic region on HSA21
that overlaps with the minimal region responsible for
Rest suppression in mouse models of DS (Figure 2B;
highlighted square).
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Figure 3. Trisomy of DYRK1A Reduces
Rest mRNA Levels in Mouse Models of DS
(A) qRT-PCR analysis of Rest and human
DYRK1A levels in undifferentiated mouse
ES cells: D3 (open bars), 47-1 (filled
bars), and 47-1 transfected with RNAi spe-
cifically targeting human DYRK1A mRNA in
the 30UTR (striped bars) (n ¼ 3 indepen-
dent transfection experiments). The data
are shown relative to control samples
transfected with nontargeting ‘‘scrambled’’
RNAi sequence.
(B) qRT-PCR analysis of Rest levels in undif-
ferentiated mouse D3 and 47-1 ES cells
(blue symbols and red symbols, respec-
tively) treated with the DYRK1A-kinase
inhibitor, green-tea compound EGCG (10
mM), for 0, 6, or 24 hr.
(C) Undifferentiated D3 mouse ES cells
were transfected with a construct contain-
ing 1013 bp of mouse Rest promoter se-
quence cloned upstream of a firefly lucifer-
ase reporter gene and were then treated
(þ) or not treated () with 10 mM EGCG
for 24 hr (ev: cells transfected with empty
vector, containing the luciferase gene
without any promoter). Horizontal bars
represent arbitrary luminescence units.
Firefly luminescence was normalized
against Renilla luciferase activity for
taking into account transfection efficiency
(n ¼ 3 independent transfection experi-
ments).
(D) qRT-PCR analysis of Rest in adult brains of TgDyrk1A mice and WT littermates (n ¼ 5). Means and standard errors are shown, and
statistical significance by Student’s t test is indicated by one (p < 0.05) or two (p < 0.01) asterisks.DYRK1A Dosage Imbalance Perturbs Rest Levels
These data, taken together, allowed us to hypothesize that
one ormore of the three genes in theminimal candidate re-
gion (TTC3, DSCR3, or DYRK1A) would control Rest tran-
script levels in mice and humans. In order to test this
hypothesis, we used RNAi oligonucleotides to speciﬁcally
silence the three genes, individually or in pairs, in normal,
pluripotent, undifferentiated mouse E14 ES cells (for
sequences of all siRNA reagents, see Table S4; silencing
effectiveness was measured by quantitative RT-PCR; see
Figure S3). Rest mRNA levels speciﬁcally responded only
to the dose of Dyrk1A and not to the other two genes
(Figure 2C). Interestingly, the level of Rest was reduced
when the Dyrk1a transcript was suppressed (Figure 2C).
We then used human-speciﬁc DYRK1A RNAi oligonucleo-
tides (targeting the 30UTR) to silence only the products of
the third copy of the DYRK1A gene in transchromosomic
47-1 ES cells. This approach only partially succeeded in sup-
pressing human DYRK1A mRNA (~0.5-fold; Figure 3A),
with no signiﬁcant effect on mouse Dyrk1A (not shown).
This correction was sufﬁcient for rescuing Rest levels to
within the range of normal (D3 control) values (Figure 3A).
This provides strong evidence that Rest dysregulation isme-
diated by DYRK1A. The effect of the selective DYRK1A-The Americankinase inhibitor, epigallocatechin gallate (EGCG),31 on Rest
expression was then assessed. Short-term culture with the
inhibitor slightly reduced Rest levels in D3 cells but had
little effect on trisomic 47-1 cells (Figure 3B). Longer treat-
ment signiﬁcantly reduced Rest levels in both cell lines as
compared with untreated cells (Figure 3B), in concordance
with the effect of complete RNAi silencing of DYRK1A
(Figure 2C, Figure S3).We also observed an inhibitory effect
of EGCG on the Rest-promoter activity in undifferentiated
ES cells (Figure 3C). Lastly, we studied Rest in brains from
adult Dyrk1A transgenic (TgDyrk1A) mice, which display
several DS-related neural phenotypes and show a 1.94-
fold increase in Dyrk1A protein levels.24 A signiﬁcant
(~30%) reduction of Rest mRNA was observed (Figure 3D),
demonstrating that the increased Dyrk1A gene dosage is
sufﬁcient to cause the suppression of Rest, to an extent
similar to that observed in brains of DS mouse models.
These data suggest that Rest expression is very sensitive
to the level of Dyrk1A, with both over- and underexpres-
sion of Dyrk1A resulting in Rest suppression. The
DYRK1A-inhibitor data implicate DYRK1A phosphoryla-
tion in the mechanism behind this effect. Our data cannot
exclude the possibility that other HSA21 genes cooperate
with DYRK1A in modulating the Rest levels. The potentialJournal of Human Genetics 83, 388–400, September 12, 2008 393
Figure 4. Trisomy 21-Caused Perturbation of the Regulatory Network Maintaining Pluripotency in Undifferentiated ES Cells Is
Sensitive to DYRK1A Activity
(A) qRT-PCR measurements of the mRNA levels of key regulators of pluripotency in undifferentiated D3 (open bars) and 47-1 (filled bars)
mouse ES cells (n ¼ 9).
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contribution of several other genes from the eQTL region
was considered: DOPEY2, which was implicated in cerebel-
lar morphogenesis,32 is not expressed at the blastocyst
stage (Unigene database), whereas Cbr1, recently high-
lighted as a strong potential candidate for the generation
of DS phenotypes,33 and Setd4 were both ruled out by
the demonstration that their respective RNAi knockdowns
had no effect on Rest levels in mouse ES cells (see
Figure S4). Much more detailed analysis would have to be
carried out for the examination of additional contributory
effects of all other HSA21 genes.
DYRK1A-Rest Deregulation Disturbs Pluripotency
and Embryonic Stem Cell Fate
Ourdata show that the level of Rest is approximatelyhalved
in undifferentiated trisomy 21 ES cells (Figure 1). It was re-
cently reported that Rest þ/ cells show reduced levels of
key regulators of pluripotency, Oct4, Nanog, and Sox2, re-
sulting in aberrantly premature expression of differentia-
tion-driving transcription factors (TFs).20 The differences
in the levels of Oct4, Nanog, and Sox2 in our microarray
data were not above the rigorous signiﬁcance cutoff thresh-
olds. However, when their expression was more sensitively
tested by qRT-PCR on a larger number of independent
cultures (n ¼ 9), a result partially overlapping with that of
Rest þ/ cells20 was obtained: Oct4 levels were not signiﬁ-
cantly changed, butNanog and Sox2were both signiﬁcantly
reduced in trisomy 21 ES cells (Figure 4A). Next, we mea-
sured the levels of several TF drivers of embryonic-layer-
speciﬁc differentiation (downstream targets ofOct4, Nanog,
and Sox2) that were increased in Restþ/ cells.20We found
that the TF drivers of endoderm (Gata4 [MIM 600576],
Gata6 [MIM 601656], and Foxa2 [MIM 600288]) andmeso-
derm (Snai1 [MIM 604238] and Pitx2 [MIM 601542]) were
all aberrantly increased in undifferentiated trisomy 21 ES
cells, whereas TF drivers of ectoderm (Fgf5 [MIM 165190])
were unchanged (Figure 4B, Tables S1 and S2). We then
demonstrated that the reduced levels of Nanog and Sox2 in
47-1 cells could be partially restored (though still not reach-
ing the levels in D3 cells; not shown) by human-speciﬁc
DYRK1A RNAi transfection (Figure 4C), similar to Rest
(Figure 3A). The partial knockdown of human DYRK1A in
this experiment did not signiﬁcantly alter the levels of line-
age-speciﬁc TFs (not shown), probably because it would
take a stronger and more lasting knockdown to stimulatethe cascade of events in the reassembly of the complexes
repressing the transcription of these TFs once they had
been derepressed. We then investigated whether the drastic
reduction in Rest caused by a 24 hr incubation with
DYRK1A-kinase inhibitor in normal mouse D3 cells had
any effects on the pluripotency-regulating network. This
treatment reduced the level of Rest in D3 cells by 3.5-fold
(Figure 3B), and it was also sufﬁcient to trigger a reduction
in the levels of Nanog and Sox2 and a premature increase in
the expression of endodermal and mesodermal TFs Foxa2,
Gata4, and Snai1 (Figure 4D). Taken together, these data
show that the pluripotency-regulating network is disturbed
in trisomy 21 ES cells in a speciﬁc way, which is similar in
part to the disturbance reported for the heterozygous knock-
out of Rest,20 and that this deregulation is partially sensitive
to the dose and enzymatic activity of DYRK1A.
Whenwe allowed the ES cells to differentiate into embry-
oid bodies (EBs), the trisomy 21 EBs (47-1) showed a signif-
icantly higher level of the primitive endoderm marker
(Gata4) and severely reduced levels of neuroectodermal
markers (Nestin [MIM 600915], Tubb3 [MIM 602661],
Map2 [MIM 157130]), compared with the normal EBs (D3)
(Figure 5A), suggesting a skewed ratio of early layer-speciﬁc
progenitor cells in favor of primitive endoderm at the ex-
pense of neuroectodermal progenitors. This was further in-
vestigated by replating the dissociated EBontoN2medium,
allowing the differentiation of neuroectodermal progeni-
tors into neurons. Trisomy 21 cells (47-1) produced a signif-
icantly reduced number of neurons per total number of
DAPI-staining nuclei and lower relative levels of Tubb3
and Map2 mRNA in the same cell population (Figures 5B
and5B0). Therewas also a trend toward an increase in abnor-
mal branching in 47-1-derived neurons, compared with D3
neurons (Figure 5C), quantiﬁed as an altered ratio of
secondary to primary neurites (see Figure S5). These data
reproduce the main features of the neurogenesis defect
previously reported for human DS fetal neurospheres.9
Discussion
Dual-speciﬁcity tyrosine-phosphorylated and -regulated
kinase, DYRK1A, is a well-characterized HSA21 gene and
ortholog of the Drosophila minibrain (mnb) gene, whose
mutation causes abnormal spacing of neuroblasts and
reduced production of neuronal progeny in Drosophila.34(B) qRT-PCR measurements of the mRNA levels of selected differentiation-driving TFs that are known downstream targets of the regulators
of pluripotency. TFs driving specific embryonic-layer lineages are color coded, as per labeled color symbols. D3 (open bars) and 47-1 (filled
bars) (n ¼ 9).
(C) qRT-PCR analysis of Sox2 and Nanog levels in undifferentiated mouse ES cells: 47-1 (filled bars) and 47-1 transfected with RNAi
specifically targeting human DYRK1A mRNA in the 30UTR (open bars) (n ¼ 3 independent transfection experiments). The data are shown
relative to the control samples transfected with nontargeting ‘‘scrambled’’ RNAi sequence.
(D) qRT-PCR analysis of the levels of regulators of pluripotency and selected lineage-specific TFs in undifferentiated normal mouse D3 cells
treated with the DYRK1A-kinase inhibitor, green-tea compound EGCG (10 mM), for 0 hr (open symbols) or 24 hr (reverse striped symbols).
TFs driving specific embryonic-layer lineages are color coded, as per labeled color symbols.
In all graphs, means and standard errors are shown, and statistical significance by Student’s t test is indicated by one (p< 0.05), two (p<
0.01), or three (p < 0.001) asterisks.
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Figure 5. Trisomy 21 ES Cells Give Rise to Embryoid Bodies with a Disturbed Composition of Lineage-Specific Progenitors
(A) qRT-PCR measurements of the mRNA levels of selected lineage-specific markers in EBs derived by culturing D3 (open bars) and 47-1
(filled bars) ES cells (n ¼ 8 experiments) in the absence of LIF, as well as in the presence of retinoic acid. Markers of specific embryonic-
layer lineages are color coded, as in Figure 4.
(B and B0) Measurement of the progress of in vitro neurogenesis of EBs from Figure 5A replated onto Neurobasal N2 medium for promoting
the differentation of neural progenitors into neurons. (B) mRNA levels of Nestin, Map2, and Tubb3, measured by qRT-PCR (n ¼ 7 exper-
iments). (B0) Proportion of cells positive for immunofluorescent staining with a neuronal marker, relative to the number of DAPI-staining
nuclei (n ¼ 2 experiments). Lower graph shows values normalized to WT D3 levels.
(C) Representative immunofluorescence images of Tubb3-positive (green) cells derived from EBs of D3 and 47-1 cells after differentiation
for 48 hr in Neurobasal N2 medium, with DAPI (blue) nuclear counterstain. See Figure S5 for quantitative analysis of neurite branching. In
all graphs, means and standard errors are shown, and statistical significance by Student’s t test is indicated by one (p < 0.05), two (p <
0.01), or three asterisks (p < 0.001).
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Dosage imbalance of DYRK1A together with DSCR1 (MIM
602917) (also on HSA21) has been reported to cause a dys-
regulation of the NFATc (MIM 602699) pathway in DS.35
This mechanism is most likely independent of the Rest dys-
regulation we report here, given thatDSCR1 is not trisomic
in two systems showing Rest reduction in our experiments
(40-2 and TC1) and that the Rest reduction we observe de-
velopmentally precedes the changes in NFATc. We report
a downregulation of RestmRNA in adult brains of three dif-
ferent DS mouse models—Tc1, Ts1Cje, and TgDyrk1A—
compared to their WT littermates (Figures 1G and 3D). In-
terestingly, all three of these mouse models and a fourth
mouse model that is trisomic for four HSA21 genes, includ-
ing DYRK1A (Tg152f7), share learning and memory deﬁ-
cits, motor defects, including hyperactivity and other be-
havioral changes, and LTP deﬁcits in the hippocampus or
other signs of hippocampal dysfunction.4–8,24 This com-
parison between the yeast artiﬁcial chromosome (YAC)-
transgenic, gene-transgenic, and segmental-trisomy
models should be taken with a degree of caution, because
even though there is a hippocampal dysfunction in both
models, the reasons behind each could be different. Also,
the impact of Dyrk1A overexpression could be different
in different genetic backgrounds within disomic or triso-
mic contexts and in different brain regions. Our data are
partly in contradiction with a recently generated 33-gene
trisomy model of DS, Ts1Rhr, that shows no hippocam-
pal-volume change and no electrophysiological and be-
havioral defects associated with hippocampal functions
despite having three copies of Dyrk1A.36 However, given
that (1) crossing the Ms1RhR reciprocal-deletion model
to the Ts65DN mouse model rescues most of the latter
model’s cognitive phenotypes36 and that (2) TgDyrk1A
mouse models show compelling phenotypes,4,24 it is likely
that additional factors, such as strain-speciﬁc modiﬁer
genes, might account for the apparent contradiction. Addi-
tional studies on the Ts1RhR mouse model are clearly
necessary to explain these discrepancies. Interestingly,
monosomy of this 33-gene segment (mouse model
Ms1RhR) produced striking reductions in hippocampal
volume,36 comparable to the severe reduction in brain
size and morphology in Dyrk1Aþ/mice37 and consistent
with the fact that truncation of DYRK1A in humans causes
microcephaly.38 This result is compatible with our observa-
tion that downregulation of Dyrk1A below physiological
(disomic) levels drastically reduces Rest level (Figure 2C,
Figure 3B), thereby deregulating early differentiation and
decreasing the relative proportion of neuroectodermal pro-
genitors. In support of this explanation, an early develop-
mental function for Rest has also been demonstrated in
other models: Rest-knockout mice exhibit early embryonic
lethality,39 and RNAi strategies in Xenopus revealed that a
reduced transcriptional dose of Rest causes incorrect pat-
terning of the ectoderm and abnormal neurogenesis.40
The observation that both overdose and inhibition of
Dyrk1A have the same consequence of reducing the Rest
transcript level is intriguing. Several different hypothesesThe Americancould explain this phenomenon. It is plausible that an
imbalance could occur in a multiprotein complex regulat-
ing REST transcription, subcomponents of which could be
DYRK1A targets. Such mechanisms have been previously
demonstrated in yeast, in which under- or overexpression
of single subunits of a multiprotein complex reduced the
ﬁtness of the complex as a whole with an equal outcome.41
We also identify the DYRK1A locus on 21q22 as the most
signiﬁcant eQTL for the control of Rest level in human lym-
phoblastoid lines (LBLs) (Figures 2A and 2B). Interestingly,
this locus, as well as the next two most likely eQTLs (9q22
and 6q27; Figure 2A), form three of the 12 loci genome-
wide, with the suggestive linkage to Alzheimer’s disease (AD,
[MIM104300]), in a studyof 437 families.42 Itmight be inter-
esting to examine the roles ofDYRK1AandREST in aging and
survival of neurons, as well as in pathogenesis of AD.
DYRK1A displays a dynamic spatio-temporal pattern of
expression during mouse brain development.43 Its expres-
sion in preneurogenic and neurogenic progenitors43 places
it at the critical point when a sudden change in the level of
Rest transcription takes place,14 after the proteolytic degra-
dation of Rest triggers the exit from ES to preneurogenic
progenitor. The transient burst of DYRK1A expression in
the asymmetric neuronal-progenitor cell division ﬁts with
its potential role as the trigger for neuro-differentiation com-
mitment.43,44 Our data suggest that one of the mechanisms
by which DYRK1A could exert this triggering role could be
through precipitating local spatio-temporal changes in the
level of Rest. Repertoire of downstream target genes regu-
lated by REST is critically dependent on the level of
REST,14,27,45 regulation and maintenance of which is not
fully understood. Differentiation is triggered by an orches-
trated reduction in Rest levels, which is mediated both by
ubiquitin-dependentproteolyticdegradationandbycontrol
of transcription.14,46 Forced partial knockout of Rest destabi-
lizes a complexnetworkofmiRNAs andproteins responsible
for the maintenance of self-renewal and pluripotency of
both human andmouse ES cells.20,47,48 This produced a pre-
mature and aberrant expression of differentiation-driving
TFs of all embryonic lineages in undifferentiated ES cells.20
Our data (Tables S1 and S2, Figures 4A and 4B) show that
the halving of Rest dose by trisomy 21 reproduces many of
these perturbations (decreased levels of Nanog and Sox2
and increased levels of Gata4, Gata6, Foxa2, Snai1, and
Pitx2), but not all of them (Oct4 and Fgf5 levels are un-
changed). The reasons for these differences are unclear and
require additional investigation, but they are likely to result
from the trisomic contribution of other HSA21 elements.
Nevertheless, the reduction in Rest has the potential to sig-
niﬁcantly perturb the pluripotency network in trisomy 21
ES cells, and this perturbance seems to be partially sensitive
to the dose and kinase activity of DYRK1A (Figures 4C and
4D).DYRK1A is localized in the cellnuclei and/orcytoplasm,
depending on the speciﬁc cell type, and some of its phos-
phorylation targets include histone subunits and TFs.49–51
The potential contribution of other HSA21 genes to this
deregulation remains to be investigated. We cannot ruleJournal of Human Genetics 83, 388–400, September 12, 2008 397
out the possibility that DYRK1A-kinase activity affects other
regions in the Rest promoter, besides affecting transcription
from the promoter region, shown in Figure 3C (though we
ruled out any signiﬁcant contribution from several other re-
gions, totaling 1393 bp of the Rest promoter; data available
on request). We also cannot rule out the possibility that
DYRK1A-kinase activity affects other unknown targets
within the complex miRNA-protein-regulatory network,
whose back- and forward-feeding loops control levels of
Rest, Oct4, Nanog, and Sox2.20,47,48
ES cells with premature expression of differentiation-
driving TFs have been reported to give rise to EBs with in-
creased lineage-speciﬁc progenitors.20 To test if this
phenomenon could be reproduced in trisomy 21 ES cells,
we differentiated the 47-1 and D3 cells for 8 days in the
absence of LIF, as well as in the presence of retinoic acid.
Consistent with the premature expression of TFs observed
in the trisomy 21 ES cells, their differentiation into EBs
resulted in a skewed ratio of lineage progenitor markers:
compared with normal (D3) cells, the trisomic (47-1) cells
produced EBs with higher levels of Gata4 (a marker of
extra-embryonic endoderm and heart development) and
reduced markers of the EB neuroectodermal compartment
(nestin, Tubb3, and Map-2) (Figure 5A). Neurogenesis start-
ing from such EBs was retarded (Figure 5B), consistent with
the prediction that the EBs contained fewer neuronal
progenitor cells relative to other progenitors. Two other
reports support these observations: (1) we have recently
shown that trisomy 21 ES cells ectopically form teratomas
displaying the full spectrum of differentiated tissues
in vivo but with a strongly reduced neuronal cell fate com-
pared with euploid controls,52 and (2) Bahn et al. have
shown that human fetal-brain neurospheres display a se-
verely reduced ability to form neurons, compared to neu-
rospheres grown from age-matched euploid feti.9 The DS
neurospheres also produced neurons with abnormally
branched neurites,9 a result reproduced by our transchro-
mosomic ES cells (Figure 5C and Figure S5) and by partial
REST siRNA knockdown in a differentiating NPC cell
line.53 Taken together, these data suggest that the
DYRK1A-REST perturbation has the potential to signiﬁ-
cantly contribute to the development of defects in neuro-
nal number and morphology in DS. The premature reduc-
tion in REST levels could skew cell-fate decisions to give
rise to a relative depletion in the number of neuronal pro-
genitors, and the same reduction in REST levels could
cause an aberrantly accelerated differentiation of each pro-
genitor, producing abnormally highly branched neurons.
In summary, we have demonstrated that Rest levels are
disturbed at a very early developmental stage in trisomy
21 ES cells (preceding ES cell differentiation) and shown
this disturbance to be dose-sensitive to the level and activ-
ity of DYRK1A. Our results suggest that this deregulation
has the potential to disturb the development of all embry-
onic lineages, warranting more detailed research into its
contribution to all aspects of DS pathology and rationales
for novel therapeutic approaches.398 The American Journal of Human Genetics 83, 388–400, SeptemSupplemental Data
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